HEMISPHERIAN AS
Developing novel small molecule drugs targeting TET2 for aggressive cancers.
Översikt
- 5
- Anställda
- 269t NOK
- Omsättning
- 2020
- Grundat
Nyckelbeslutsfattare
Roger Stupp
Chair of the Clinical Advisory Board
Michael Lim
Member of the Clinical Advisory Board
Monika Hegi
Member of the Clinical Advisory Board
Einar O. Vik-Mo
Member of the Clinical Advisory Board
+2 fler kontakter i Funnelfeedr
Beskrivning
Hemispherian is an innovative preclinical pharmaceutical company dedicated to redefining targeted cancer therapeutics. The core focus is developing a novel class of small molecule drugs that specifically target the TET2 enzyme. These compounds are designed as targeted therapies for particularly aggr...